The polymorphism of human HMOX1 promoter has been in our interest for a long time. We showed, that it matters when it comes to the resistance of human endothelial cells to oxidative stress. This time, we show that short HMOX1 promoter allele is more frequent in childhood acute lymphoblastic leukemia patients than in control group. It is associated with higher risk of treatment failure and chemotherapy-induced neutropenia.
You can find more here:
Bukowska-Strakova, K. Włodek, J.; Pitera, E.; Kozakowska, M.; Konturek-Cieśla, A.; Cieśla, M.; Gońka, M.; Nowak, W.; Wieczorek, A.; Pawińska-Wąsikowska, K.; Józkowicz, A.; Siedlar, M. Role of HMOX1 Promoter Genetic Variants in Chemoresistance and Chemotherapy Induced Neutropenia in Children with Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2021, 22, 988
Comments